The Cannabis plant has been used for many of years as a medicinal agent in the relief of
pain and seizures. It contains approximately 540 natural compounds including more than …

Neuropathic pain, caused by a lesion or disease affecting the somatosensory system, affects
between 3 and 17% of the general population. The treatment of neuropathic pain is …

Fibromyalgia (FM) is a syndrome that does not present a well-defined underlying organic
disease. FM is a condition which has been associated with diseases such as infections …

Dysregulation of the endogenous lipid mediators endocannabinoids and their G-protein-
coupled cannabinoid receptors 1 and 2 (CB1R and CB2R) has been implicated in a variety …

A great need exists for the development of new medications to treat pain resulting from
various disease states and types of injury. Given that the endogenous cannabinoid (that is …

Chronic pain states are highly prevalent and yet poorly controlled by currently available
analgesics, representing an enormous clinical, societal, and economic burden. Existing pain …

The discovery of cannabinoid receptors and subsequent identification of their endogenous
ligands (endocannabinoids) in early 1990s have greatly accelerated research on …

Despite being regarded as a hippie science for decades, cannabinoid research has finally
found its well-deserved position in mainstream neuroscience. A series of groundbreaking …

Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key
regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the …

The transition from acute to chronic pain appears to occur in discrete pathophysiological and
histopathological steps. Stimuli initiating a nociceptive response vary, but receptors and …